Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

89 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Rapid dose-dependent Natural Killer (NK) cell modulation and cytokine responses following human rVSV-ZEBOV Ebolavirus vaccination.
Pejoski D, de Rham C, Martinez-Murillo P, Santoro F, Auderset F, Medaglini D, Pozzi G, Vono M, Lambert PH, Huttner A, Haks MC, Ottenhoff THM, Villard J, Siegrist CA; VEBCON Consortium; VSV-EBOVAC Consortium; VSV-EBOPLUS Consortium. Pejoski D, et al. Among authors: haks mc. NPJ Vaccines. 2020 Apr 14;5(1):32. doi: 10.1038/s41541-020-0179-4. eCollection 2020. NPJ Vaccines. 2020. PMID: 32337075 Free PMC article.
Discovery and validation of a prognostic proteomic signature for tuberculosis progression: A prospective cohort study.
Penn-Nicholson A, Hraha T, Thompson EG, Sterling D, Mbandi SK, Wall KM, Fisher M, Suliman S, Shankar S, Hanekom WA, Janjic N, Hatherill M, Kaufmann SHE, Sutherland J, Walzl G, De Groote MA, Ochsner U, Zak DE, Scriba TJ; ACS and GC6–74 cohort study groups. Penn-Nicholson A, et al. PLoS Med. 2019 Apr 16;16(4):e1002781. doi: 10.1371/journal.pmed.1002781. eCollection 2019 Apr. PLoS Med. 2019. PMID: 30990820 Free PMC article.
Clinical immunology and multiplex biomarkers of human tuberculosis.
Walzl G, Haks MC, Joosten SA, Kleynhans L, Ronacher K, Ottenhoff TH. Walzl G, et al. Among authors: haks mc. Cold Spring Harb Perspect Med. 2014 Dec 4;5(4):a018515. doi: 10.1101/cshperspect.a018515. Cold Spring Harb Perspect Med. 2014. PMID: 25475107 Free PMC article. Review.
Human CD8+ T-cells recognizing peptides from Mycobacterium tuberculosis (Mtb) presented by HLA-E have an unorthodox Th2-like, multifunctional, Mtb inhibitory phenotype and represent a novel human T-cell subset.
van Meijgaarden KE, Haks MC, Caccamo N, Dieli F, Ottenhoff TH, Joosten SA. van Meijgaarden KE, et al. Among authors: haks mc. PLoS Pathog. 2015 Mar 24;11(3):e1004671. doi: 10.1371/journal.ppat.1004671. eCollection 2015 Mar. PLoS Pathog. 2015. PMID: 25803478 Free PMC article. Clinical Trial.
Ebola vaccine R&D: Filling the knowledge gaps.
Medaglini D, Harandi AM, Ottenhoff TH, Siegrist CA; VSV-Ebovac Consortium. Medaglini D, et al. Sci Transl Med. 2015 Dec 9;7(317):317ps24. doi: 10.1126/scitranslmed.aad3106. Sci Transl Med. 2015. PMID: 26659569 Free PMC article. Review.
A dose-dependent plasma signature of the safety and immunogenicity of the rVSV-Ebola vaccine in Europe and Africa.
Huttner A, Combescure C, Grillet S, Haks MC, Quinten E, Modoux C, Agnandji ST, Brosnahan J, Dayer JA, Harandi AM, Kaiser L, Medaglini D, Monath T; VEBCON and VSV-EBOVAC Consortia; Roux-Lombard P, Kremsner PG, Ottenhoff TH, Siegrist CA. Huttner A, et al. Among authors: haks mc. Sci Transl Med. 2017 Apr 12;9(385):eaaj1701. doi: 10.1126/scitranslmed.aaj1701. Sci Transl Med. 2017. PMID: 28404856 Free PMC article.
Molecular Signatures of Immunity and Immunogenicity in Infection and Vaccination.
Haks MC, Bottazzi B, Cecchinato V, De Gregorio C, Del Giudice G, Kaufmann SHE, Lanzavecchia A, Lewis DJM, Maertzdorf J, Mantovani A, Sallusto F, Sironi M, Uguccioni M, Ottenhoff THM. Haks MC, et al. Front Immunol. 2017 Nov 15;8:1563. doi: 10.3389/fimmu.2017.01563. eCollection 2017. Front Immunol. 2017. PMID: 29204145 Free PMC article. Review.
Determinants of antibody persistence across doses and continents after single-dose rVSV-ZEBOV vaccination for Ebola virus disease: an observational cohort study.
Huttner A, Agnandji ST, Combescure C, Fernandes JF, Bache EB, Kabwende L, Ndungu FM, Brosnahan J, Monath TP, Lemaître B, Grillet S, Botto M, Engler O, Portmann J, Siegrist D, Bejon P, Silvera P, Kremsner P, Siegrist CA; VEBCON; VSV-EBOVAC; VSV-EBOPLUS Consortia. Huttner A, et al. Lancet Infect Dis. 2018 Jul;18(7):738-748. doi: 10.1016/S1473-3099(18)30165-8. Epub 2018 Apr 5. Lancet Infect Dis. 2018. PMID: 29627147 Free PMC article.
89 results